top of page
Search

RevealDX obtains FDA Clearance

  • Writer: Ryan Brevard
    Ryan Brevard
  • Feb 3
  • 2 min read

February 3, 2026


Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules,announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification inNovember of 2025.

The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index(mSI™), a score that is intended to help radiologists make

more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on over 1,500 patients from a variety of cohorts.

The RevealAI-Lung CADx device has several features, including:


● Significant improvement in Radiologist reader AUC delta

● Use of real world NLST data as our reference population

● Clinically relevant malignancy scoring

● First ever integration directly into PACS, vastly improving workflow

● Generalizability across exam types and patient populations


The software can be purchased directly from RevealDx or through the company’s US distributor, Sirona. Thecompany previously announced it has integrated with Riverain, the leading lung nodule detection company inthe US, as well as Fuji PACS. With this FDA clearance, RevealAI-Lung is now reimbursable by Medicare usingcodes 0721T and 0722T.


“We are excited to announce that RevealAI-Lung will now be available in the US” said Chris Wood, CEO ofRevealDx. “We would like to thank our clinical collaborators for their help in achieving this milestone. We aremost excited about the anticipated positive impact on patient care that will result from the use of RevealAI-Lung.”


About RevealDx RevealDx has developed RevealAI-Lung, the first Medical Imaging AI software to achieve reimbursement inEurope. The company has published several studies demonstrating significant improvement in both early cancerdetection as well as reduction in false positives. Studies show that by integrating this patented technology intoroutine clinical use, healthcare providers can more effectively triage lung nodules. For more information,contact sales@reveal-dx.com. RevealAI-Lung is distributed in the EU by contextflow.

 
 
 

Comments


bottom of page